Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12

International Journal of Cancer

Volumn 128, Issue 3, 2011, Pages 715-725

  Lis, Raphael ^a,b   Touboul, Cyril ^a,b   Mirshahi, Pejman ^b   Ali, Fadoua ^a   Mathew, Sharon ^a   Nolan, Daniel J ^c   Maleki, Mahtab ^a   Abdalla, Salma A ^a   Raynaud, Christophe M ^a   Querleu, Denis ^d,e   Al Azwani, Eman ^a   Malek, Joel ^a   Mirshahi, Massoud ^b   Rafii, Arash ^a,f  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e MCGILL UNIVERSITY   (Canada)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CXCL12; hyperthermia; mesenchymal stem cells; ovarian cancer resistance

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER RESISTANCE; CASE REPORT; CELL INTERACTION; CELL PROTECTION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; HEAT TOLERANCE; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; MESENCHYMAL STEM CELL; OVARY ADENOCARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STROMA CELL; THERAPY EFFECT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINE CXCL12; COCULTURE TECHNIQUES; FEMALE; FLOW CYTOMETRY; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HOT TEMPERATURE; HUMANS; HYPERTHERMIA, INDUCED; MESENCHYMAL STEM CELLS; OVARIAN NEOPLASMS; RECEPTORS, CXCR4; SURVIVAL RATE;

EID: 78649841894     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25619     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Bhoola SMD, Hoskins WJMD,. Diagnosis and Management of Epithelial Ovarian Cancer. Obstet Gynecol 2006; 107: 1399-410.
3. Eisenkop SM, Spirtos NM, Lin W-CM,. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 2006; 103: 329-35.
4. Pfisterer J, Ledermann JA,. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006; 33: 12-16.
5. Di Nicolantonio F, Mercer S, Knight L, Gabriel F, Whitehouse P, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers S, Toh S, et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005; 5: 78.
6. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
7. Markman M, Brady MP, Hutson AP, Berek JSMD,. Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the gynecologic oncology group experience. Int J Gynecol Cancer 2009; 19: 223-9.
8. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan T, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 2007; 14: 128-33.
9. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM,. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3: 487-97.
10. Jones EL, Samulski TV, Dewhirst MW, Alvarez-Secord A, Berchuck A, Clarke-Pearson D, Havrilesky LJ, Soper J, Prosnitz LR,. A pilot phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer 2003; 98: 277-82.
11. Meyn RE, Corry PM, Fletcher SE, Demetriades M,. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res 1980; 40: 1136-39.
12. van de Vaart PJM, van der Vange N, Zoetmulder FAN, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC,. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34: 148-54.
13. Roti Roti JL,. Cellular responses to hyperthermia (40-46°C): cell killing and molecular events. Int J Hyperthermia 2009; 24: 3-15.
14. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, Sumida M, Ohkubo H,. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997; 79: 884-91.
15. Helm CW, Toler CR, Martins RS, III, Gordinier ME, Parker LP, Metzinger DS, Edwards RP,. Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity. Int J Gynecol Cancer 2007; 17: 204-09.
16. Chua T, Robertson G, Liauw W, Farrell R, Yan T, Morris D,. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 2009; 135: 1637-45.
17. Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, Classe JM, Bereder JM, Quenet F, Meeus P, Marchal F, Morice P, Elias D,. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 2010; 36: 589-93.
18. Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH, Kim SJ,. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol 2010; 101: 149-55.
19. Ceelen WPF, Michael F,. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 2009; 7: 108-15.
20. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T,. The tumor-promoting actions of TNF-Å'± involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009; 119: 3011-23.
21. Katz E, Skorecki K, Tzukerman M,. Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations. Clin Cancer Res 2009; 15: 70-80.
22. Tsiatas ML, Gyftaki R, Liacos C, Politi E, Rodolakis A, Dimopoulos MA, Bamias A,. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy. Int J Gynecol Cancer 2009; 19: 1329-34.
23. Rafii A, Mirshahi P, Poupot M, Faussat A-M, Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J, Bergalet J, Querleu D, et al. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS ONE 2008; 3: e3894.
24. Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J, Mirshahi M, Couderc B,. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 2010; 126: 2090-101.
25. Martinet L, Poupot R, Mirshahi P, Rafii A, FourniÈ J-J, Mirshahi M, Poupot M,. Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer 2010; 126: 2143-52.
26. Huang DW, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 2008; 4: 44-57.
27. Dennis G, Sherman B, Hosack D, Yang J, Gao W, Lane HC, Lempicki R,. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: P3.
28. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F,. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008; 122: 91-99.
29. Dubeau L,. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008; 9: 1191-97.
30. Burleson KM, Hansen LK, Skubitz APN,. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis 2005; 21: 685-97.
31. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM,. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 2005; 11: 113-22.
32. Caplan AI,. Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng 2005; 11: 1198-211.
33. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR,. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-47.
34. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M, Marini FC,. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009; 27: 2614-23.
35. Lee MJ, Jeon ES, Lee JS, Cho M, Suh D-S, Chang CL, Kim JH,. Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells. J Cell Biochem 2008; 104: 499-510.
36. Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, zu Bentrup KH, Danka ES, Henkle SL, Scandurro AB,. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci USA 2009; 106: 3806-11.
37. Cho JA, Park H, Kim HK, Lim EH, Seo SW, Choi JS, Lee KW,. Hyperthermia-treated mesenchymal stem cells exert antitumor effects on human carcinoma cell line. Cancer 2009; 115: 311-23.
38. Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh D-S, Yoon M-S, Chang CL, Jung JS, Kim JH,. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells 2008; 26: 789-97.
39. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F,. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009; 4: e4992.
40. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR,. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930-38.
41. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, Emilie D, Terrassa M, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005; 65: 465-72.
42. Yuecheng Y, Xiaoyan X,. Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2. [Article]. Eur J Cancer Prev 2007; 16: 430-35.
43. Guo Z, Cai S, Fang R, Chen H, Du J, Tan Y, Ma W, Hu H, Cai S, Liu Y,. The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells. Colloids Surf B Biointerfaces 2007; 60: 1-6.
44. Susana M,. Campos SG. A current review of targeted therapeutics for ovarian cancer. J Oncol 2009; 2010: 11.